Home
OLV Overview
The Office of Licensing & Ventures (OLV) is responsible for patents, technology licenses and new venture development for Duke University and Medical Center. Through direct, daily interaction with faculty, small and large businesses, and venture investors, we build strong relationships and strong agreements to translate academic discoveries into commercial products that benefit society, impact public health, and improve the quality of life.
Featured Technologies
Novel antimicrobial compounds for treating Gram-negative infections
Latest News
Celsion Announces Issuance of U.S. Patent Covering ThermoDox(R) Technologies
April 13, 2011
New Patent Extends U.S. Intellectual Property Protection of ThermoDox(R) and Other Temperature-Sensitive Liposomal Formulations to 2021
Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer
November 11, 2010
Cellona Therapeutics, Inc. Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant for CT-10 Novel Targeted Cancer Compound
November 3, 2010
Cellona Therapeutics, Inc. and Duke Announce Exclusive Licensing Agreement and Collaboration to Develop Novel Cancer Drugs
September 14, 2010
Trevena Secures $35 Million in Series B Funding
July 14, 2010
Argos Therapeutics Presents Positive Phase 2 Data for Arcelis™ Dendritic Cell-based Immunotherapy in Advanced RCC at ASCO
June 8, 2010
-Interim Data in Combination with Sunitinib Demonstrate Positive Clinical Activity-
GrassRoots selected to participate in NCBC Industrial Fellowship Program
April 22, 2010
Trevena Initiates Clinical Development of TRV120027, a First-in-Class Biased Ligand
April 14, 2010
Bioptigen, Inc. Receives 2008 Frost & Sullivan North America
March 10, 2010
PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals
January 7, 2010
REGADO BIOSCIENCES, INC. COMPLETES $40 MILLION SERIES D FINANCING
December 17, 2009
Trevena Awarded $7.65 Million NIH Grant
November 3, 2009
Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study
October 22, 2009
Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue
Centice Corporation closes on $6.1 million Series C financing
October 21, 2009
Funds to support commercialization of innovative PASS Rx® system